Wecome Pharmaceutical Co Ltd (300878) — Cash Flow Reinvestment Rate
Wecome Pharmaceutical Co Ltd (300878) has a Cash Flow Reinvestment Rate of 0.03x as of June 2025, reinvesting CN¥1.47 Million (capex CN¥389.97K plus investments CN¥-1.08 Million) from operating cash flow of CN¥50.89 Million. Explore 300878 capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Wecome Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2013–2023)
Historical reinvestment intensity for Wecome Pharmaceutical Co Ltd across 10 annual periods. Also explore Wecome Pharmaceutical Co Ltd assets under control for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Wecome Pharmaceutical Co Ltd (2013–2023)
Year-by-year capital reinvestment analysis for Wecome Pharmaceutical Co Ltd. For live market cap and broader valuation context, see Wecome Pharmaceutical Co Ltd market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 6.52x | CN¥379.85 Million | CN¥58.29 Million | CN¥139.29 Million | ▲ +38.0% |
| 2022 | 4.72x | CN¥692.26 Million | CN¥146.57 Million | CN¥248.44 Million | ▲ +17.4% |
| 2020 | 4.02x | CN¥172.30 Million | CN¥42.81 Million | CN¥152.34 Million | ▲ +236.3% |
| 2019 | 1.20x | CN¥134.94 Million | CN¥112.76 Million | CN¥114.98 Million | ▼ -34.4% |
| 2018 | 1.83x | CN¥192.69 Million | CN¥105.57 Million | CN¥172.73 Million | ▼ -14.6% |
| 2017 | 2.14x | CN¥62.00 Million | CN¥29.00 Million | CN¥42.04 Million | ▲ +124.2% |
| 2016 | 0.95x | CN¥95.51 Million | CN¥100.15 Million | CN¥47.97 Million | ▼ -26.6% |
| 2015 | 1.30x | CN¥38.48 Million | CN¥29.63 Million | CN¥38.48 Million | ▲ +46.9% |
| 2014 | 0.88x | CN¥40.68 Million | CN¥46.01 Million | CN¥40.68 Million | ▲ +100.2% |
| 2013 | 0.44x | CN¥11.48 Million | CN¥25.98 Million | CN¥11.48 Million | — |